Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).
Palliative treatment of chronic neurologic disorders.
Metabolomics of Neurodegenerative Diseases.
Phosphorus-Based Dendrimer ABP Treats Neuroinflammation by Promoting IL-10-Producing CD4(+) T Cells.
The Nogo/ Nogo-66 receptor (NgR) signal is involved in neuroinflammation through the regulation of microglia inflammatory mediator expression.
Mucosal-Associated Invariant T Cells in Multiple Sclerosis: The Jury is Still Out.
Molecular analysis of polimorphisms in HLA-CLASS II DRB1* and IL7Rα possibly associated with multiple sclerosis susceptibility in a population sample of Rio de Janeiro.
Functional correlates of cognitive dysfunction in multiple sclerosis: A multicenter fMRI Study.
Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis.
3D models of human ERα and ERβ complexed with 5-androsten-3β,17β-diol.
Diffusion tensor imaging of the trigeminal nerve in patients with trigeminal neuralgia due to multiple sclerosis.
A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment.
Markedly Increased IP-10 Production by Blood-Brain Barrier in Neuromyelitis Optica.
Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis.
A novel synthetic compound MCAP suppresses LPS-induced murine microglial activation in vitro via inhibiting NF-kB and p38 MAPK pathways.
Epigenetic in Multiple Sclerosis: Molecular mechanisms and dietary intervention.
White Matter Injury in Ischemic Stroke.
LXR Agonists: New Potential Therapeutic Drug for Neurodegenerative Diseases.
[Assessment of exposure to tobacco smoke in a selected group of patients with multiple sclerosis from the Upper Silesia region].
Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.
Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
Employment and multiple sclerosis in new zealand.
EN FACE OPTICAL COHERENCE TOMOGRAPHY OF MACULAR MICROCYSTS DUE TO OPTIC NEUROPATHY FROM NEUROMYELITIS OPTICA.
Neuromyelitis optica spectrum disorders: An update.
Casein kinases as potential therapeutic targets.

Pages